- Home
- SILC vs BNTC Comparison
SILC vs BNTC Comparison
Compare SILC & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- BNTC
- Stock Information
- Founded
- SILC 1987
- BNTC 1995
- Country
- SILC Israel
- BNTC United States
- Employees
- SILC N/A
- BNTC N/A
- Industry
- SILC Computer Manufacturing
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- SILC Technology
- BNTC Health Care
- Exchange
- SILC Nasdaq
- BNTC Nasdaq
- Market Cap
- SILC 86.9M
- BNTC 88.1M
- IPO Year
- SILC 1994
- BNTC N/A
- Fundamental
- Price
- SILC $14.23
- BNTC $10.68
- Analyst Decision
- SILC Hold
- BNTC Strong Buy
- Analyst Count
- SILC 1
- BNTC 5
- Target Price
- SILC N/A
- BNTC $22.60
- AVG Volume (30 Days)
- SILC 11.5K
- BNTC 33.8K
- Earning Date
- SILC 10-31-2024
- BNTC 11-14-2024
- Dividend Yield
- SILC N/A
- BNTC N/A
- EPS Growth
- SILC N/A
- BNTC N/A
- EPS
- SILC N/A
- BNTC N/A
- Revenue
- SILC $62,386,000.00
- BNTC N/A
- Revenue This Year
- SILC N/A
- BNTC N/A
- Revenue Next Year
- SILC $4.15
- BNTC N/A
- P/E Ratio
- SILC N/A
- BNTC N/A
- Revenue Growth
- SILC N/A
- BNTC N/A
- 52 Week Low
- SILC $11.35
- BNTC $2.69
- 52 Week High
- SILC $19.04
- BNTC $12.89
- Technical
- Relative Strength Index (RSI)
- SILC 55.56
- BNTC 53.25
- Support Level
- SILC $13.75
- BNTC $10.25
- Resistance Level
- SILC $14.55
- BNTC $10.89
- Average True Range (ATR)
- SILC 0.52
- BNTC 0.43
- MACD
- SILC 0.03
- BNTC -0.07
- Stochastic Oscillator
- SILC 65.91
- BNTC 69.39
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.